Trial Started for New Ovarian Cancer Treatment
Patients with platinum-resistant ovarian cancer are testing a novel drug that inhibits the MYC protein.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should medical research prioritize funding for experimental treatments for patients with limited options?
Persevere Therapeutics has administered the first dose of misetionamide to a patient in a new Phase 2a clinical trial. This study explores the drug as a potential treatment option for those diagnosed with platinum-resistant ovarian cancer.
Why it matters
Ovarian cancer affects approximately 21,000 Americans annually, with 12,400 deaths occurring, and those with platinum-resistant cases face few therapeutic options. This trial aims to address that clinical gap by testing a drug that targets tumor growth mechanisms directly.
This open-label, single-arm Phase 2a trial is currently enrolling 18 patients across four U.S. academic cancer centers. Researchers are testing misetionamide as a standalone treatment, though these are preliminary findings as the study is just beginning.
The players
Persevere Therapeutics
A pharmaceutical developer focused on bringing new drug candidates into clinical trials for complex oncology conditions.
Abramson Cancer Center
A Philadelphia-based comprehensive cancer center that serves as the initial clinical trial site.
Beth Israel Deaconess Medical Center
A Boston-based academic medical center scheduled to begin patient screening for the trial.
University of Kansas Cancer Center
An academic oncology research facility in Kansas City expected to open enrollment for the trial.
The details
Misetionamide functions as an inhibitor of the MYC protein, a cellular factor that often drives the aggressive growth and unchecked proliferation of cancer cells. By blocking this protein, the drug seeks to interrupt the tumor's survival pathways. The study is currently underway at the Abramson Cancer Center.
Timeline
September 28, 2026: The first patient received the initial dose of the study drug.
October 2026: Additional screening is expected to begin at participating medical centers.
Health Landscape
The development of MYC-targeting therapies represents a significant shift in oncology, aiming to address proteins previously considered difficult to inhibit. This trial follows the standard investigative pattern of the National Cancer Institute's Experimental Therapeutics Clinical Trials Network.
Patients currently managing platinum-resistant ovarian cancer should discuss with their oncologist whether clinical trials for MYC inhibitors like misetionamide might be appropriate for their care plan. It is vital to consult your physician to evaluate if you meet the specific enrollment criteria for such studies.
The takeaway
Targeting the MYC protein offers a new theoretical pathway for stopping tumor growth in resistant ovarian cancers. Patients should keep track of emerging phase 2 trials by checking official research registries with their medical team.
Further reading
To learn more about current breakthroughs in oncology, visit our Cancer section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Should medical research prioritize funding for experimental treatments for patients with limited options?
